Hybrid lipid-polymer nanoparticles for sustained siRNA delivery and gene silencing

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 5, 2014, Pages e897-e900

  Shi, Jinjun ^a   Xu, Yingjie ^b   Xu, Xiaoyang ^a   Zhu, Xi ^a,d   Pridgen, Eric ^c   Wu, Jun ^a   Votruba, Alexander R ^a   Swami, Archana ^a   Zetter, Bruce R ^b   Farokhzad, Omid C ^a,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c Massachusetts Institute of Technology   (United States)

^d SICHUAN UNIVERSITY   (China)

^e KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Cancer; Gene silencing; Lipid polymer nanoparticle; SiRNA; Sustained release

Indexed keywords

BIOCOMPATIBILITY; BIODEGRADABLE POLYMERS; CLINICAL RESEARCH; GENETIC ENGINEERING; LANTHANUM COMPOUNDS; LIPOSOMES; MOLECULAR BIOLOGY; NANOPARTICLES; RNA;

CANCER; GENE SILENCING; POLYMER NANOPARTICLES; SIRNA; SUSTAINED RELEASE;

GENE THERAPY;

LIPOFECTAMINE; LUCIFERASE; NANOCARRIER; PROHIBITIN; SMALL INTERFERING RNA; LIPID; NANOPARTICLE; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCOMPATIBILITY; CANCER GENE THERAPY; CANCER INHIBITION; CARCINOMA CELL LINE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE SILENCING; GENETIC TRANSFECTION; HELA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL GENE DELIVERY SYSTEM; NANOMEDICINE; NANOPHARMACEUTICS; NEOPLASM; NONHUMAN; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE PREPARATION; TUMOR XENOGRAFT; CHEMISTRY; TUMOR CELL LINE;

CELL LINE, TUMOR; GENE SILENCING; HELA CELLS; HUMANS; LIPIDS; NANOPARTICLES; POLYMERS; RNA, SMALL INTERFERING;

EID: 84903549622     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.03.006     Document Type: Article

References (20)

1. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009, 8:129-138.
2. Pecot C.V., Calin G.A., Coleman R.L., Lopez-Berestein G., Sood A.K. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 2011, 11:59-67.
3. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
4. Burnett J.C., Rossi J.J., Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J 2011, 6:1130-1146.
5. Strumberg D., Schultheis B., Traugott U., Vank C., Santel A., Keil O., et al. Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int J Clin Pharmacol Ther 2012, 50:76-78.
6. Tabernero J., Shapiro G.I., et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 2013, 3:406-417.
7. Krebs M.D., Alsberg E. Localized, targeted, and sustained siRNA delivery. Chem Eur J 2011, 17:3054-3062.
8. Nelson C.E., Gupta M.K., Adolph E.J., Shannon J.M., Guelcher S.A., Duvall C.L. Sustained local delivery of siRNA from an injectable scaffold. Biomaterials 2012, 33:1154-1161.
9. Xue H.Y., Wong H.L. Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization. Biomaterials 2011, 32:2662-2672.
10. Ishikawa H., Nakamura Y., Jo J., Tabata Y. Gelatin nanospheres incorporating siRNA for controlled intracellular release. Biomaterials 2012, 33:9097-9104.
11. Shi J., Xiao Z., Votruba A.R., Vilos C., Farokhzad O.C. Differentially charged hollow core/shell lipid-polymer-lipid hybrid nanoparticles for small interfering RNA delivery. Angew Chem Int Ed Engl 2011, 50:7027-7031.
12. Sievers C., Billig G., Gottschalk K., Rudel T. Prohibitins are required for cancer cell proliferation and adhesion. PLoS One 2010, 5:e12735.
13. Theiss A.L., Sitaraman S.V. The role and therapeutic potential of prohibitin in disease. Biochim Biophys Acta 1813, 2011:1137-1143.
14. Patel N., Chatterjee S.K., Vrbanac V., Chung I., Mu C.J., Olsen R.R., et al. Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells. Proc Natl Acad Sci U S A 2010, 107:2503-2508.
15. Farokhzad O.C., Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev 2006, 58:1456-1459.
16. Hrkach J, Von Hoff D, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012;4:128ra39.
17. Shi J., Xiao Z., Kamaly N., Farokhzad O.C. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc Chem Res 2011, 44:1123-1134.
18. Kamaly N., Xiao Z., Valencia P.M., Radovic-Moreno A.F., Farokhzad O.C. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 2012, 41:2971-3010.
19. Creixell M., Peppas N.A. Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. Nano Today 2012, 7:367-379.
20. Hu C.M., Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol 2012, 83:1104-1111.